# Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

> **NCT01660906** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 39 (actual)

## Conditions studied

- Chronic Phase Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01660906
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01660906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01660906, "Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01660906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*